GNOM.L vs. SBIO.L
GNOM.L (Global X Genomics & Biotechnology UCITS ETF) and SBIO.L (Invesco Nasdaq Biotech UCITS ETF) are both Health & Biotech Equities funds - GNOM.L tracks the Global X Genomics & Biotechnology UCITS ETF while SBIO.L tracks the NASDAQ Biotechnology TR USD. Both are passively managed. Over the past 3 years, GNOM.L returned 4.58%/yr vs 17.44%/yr for SBIO.L. Their correlation of 0.84 suggests significant overlap in exposure. GNOM.L charges 0.50%/yr vs 0.40%/yr for SBIO.L.
Performance
GNOM.L vs. SBIO.L - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, GNOM.L achieves a 22.10% return, which is significantly higher than SBIO.L's 14.76% return.
GNOM.L
- 1D
- -0.17%
- 1M
- 11.69%
- 6M
- 15.71%
- YTD
- 22.10%
- 1Y
- 62.79%
- 3Y*
- 4.58%
- 5Y*
- —
- 10Y*
- —
SBIO.L
- 1D
- 0.44%
- 1M
- 9.18%
- 6M
- 12.82%
- YTD
- 14.76%
- 1Y
- 49.55%
- 3Y*
- 17.44%
- 5Y*
- 5.79%
- 10Y*
- 8.95%
GNOM.L vs. SBIO.L - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
GNOM.L Global X Genomics & Biotechnology UCITS ETF | 22.10% | 19.30% | -17.99% | -5.77% | -37.21% | -8.59% |
SBIO.L Invesco Nasdaq Biotech UCITS ETF | 14.76% | 32.89% | -2.00% | 6.15% | -11.85% | -5.71% |
Correlation
The correlation between GNOM.L and SBIO.L is 0.82, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.82 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.83 |
Correlation (All Time) Calculated using the full available price history since Nov 2, 2021 | 0.84 |
The correlation between GNOM.L and SBIO.L has been stable across timeframes, ranging from 0.82 to 0.84 - a consistent structural relationship.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GNOM.L vs. SBIO.L — Risk / Return Rank
GNOM.L
SBIO.L
GNOM.L vs. SBIO.L - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Global X Genomics & Biotechnology UCITS ETF (GNOM.L) and Invesco Nasdaq Biotech UCITS ETF (SBIO.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| GNOM.L | SBIO.L | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.31 | ||
| Sortino ratioReturn per unit of downside risk | -0.41 | ||
| Omega ratioGain probability vs. loss probability | 1.34 | 1.39 | -0.05 |
| Calmar ratioReturn relative to maximum drawdown | 3.35 | 6.45 | -3.10 |
| Martin ratioReturn relative to average drawdown | 9.16 | 19.17 | -10.00 |
Loading charts...
Drawdowns
GNOM.L vs. SBIO.L - Drawdown Comparison
The maximum GNOM.L drawdown since its inception was -69.32%, which is greater than SBIO.L's maximum drawdown of -39.44%. Use the drawdown chart below to compare losses from any high point for GNOM.L and SBIO.L.
Loading charts...
Drawdown Indicators
| GNOM.L | SBIO.L | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -69.32% | -39.44% | -29.88% |
Max Drawdown (1Y)Largest decline over 1 year | -18.91% | -7.65% | -11.26% |
Max Drawdown (3Y)Largest decline over 3 years | -44.77% | -26.89% | -17.88% |
Max Drawdown (5Y)Largest decline over 5 years | — | -38.33% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -38.33% | — |
Current DrawdownCurrent decline from peak | -37.11% | -4.15% | -32.96% |
Average DrawdownAverage peak-to-trough decline | -47.16% | -16.68% | -30.48% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.92% | 2.58% | +4.34% |
Volatility
GNOM.L vs. SBIO.L - Volatility Comparison
Global X Genomics & Biotechnology UCITS ETF (GNOM.L) has a higher volatility of 8.41% compared to Invesco Nasdaq Biotech UCITS ETF (SBIO.L) at 6.42%. This indicates that GNOM.L's price experiences larger fluctuations and is considered to be riskier than SBIO.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GNOM.L | SBIO.L | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.41% | 6.42% | +1.99% |
Volatility (6M)Calculated over the trailing 6-month period | 22.18% | 15.51% | +6.67% |
Volatility (1Y)Calculated over the trailing 1-year period | 29.87% | 20.35% | +9.52% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 33.11% | 21.26% | +11.85% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 33.11% | 22.15% | +10.96% |
GNOM.L vs. SBIO.L - Expense Ratio Comparison
GNOM.L has a 0.50% expense ratio, which is higher than SBIO.L's 0.40% expense ratio.
Dividends
GNOM.L vs. SBIO.L - Dividend Comparison
Neither GNOM.L nor SBIO.L has paid dividends to shareholders.
Frequently Asked Questions
GNOM.L and SBIO.L have a correlation of 0.82, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, SBIO.L is cheaper at 0.40% per year. The better choice depends on whether you care most about return, fees, risk, or income.
SBIO.L is cheaper with a 0.40% expense ratio, compared with 0.50% for GNOM.L.
GNOM.L tracks Global X Genomics & Biotechnology UCITS ETF, while SBIO.L tracks NASDAQ Biotechnology TR USD. They also come from different issuers: Global X and Invesco. Their fees differ too: 0.50% for GNOM.L and 0.40% for SBIO.L.
Find the right allocation for GNOM.L and SBIO.L
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer